Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2006, p. 4186-4188, Vol. 50, No. 12
0066-4804/06/$08.00+0 doi:10.1128/AAC.00494-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Pharmacokinetics of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Healthy Male Caucasian Volunteers
Takahiro Shibayama,1*
Yoko Matsushita,1
Takashi Hirota,1
Toshihiko Ikeda,1 and
Shogo Kuwahara2
Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan,1
Toho University School of Medicine, Ohta-ku, Tokyo, Japan2
Received 21 April 2006/
Returned for modification 10 August 2006/
Accepted 10 September 2006
The CS-023 concentration in plasma after administration by infusion to healthy volunteers at a dose of 700 mg was decreased, with a half-life of 1.7 h, and the cumulative urinary excretion was 59.4% of the dose. The total clearance, renal clearance, and volume of distribution were 8.12 liters/h, 4.14 liters/h, and 17.2 liters, respectively.
* Corresponding author. Mailing address: Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., 2-58 Hiromachi 1-chome, Shinagawa-ku, Tokyo 140-8710, Japan. Phone: 81-3-3492-3131. Fax: 81-3-5436-8567. E-mail:
sibaya{at}sankyo.co.jp.
Published ahead of print on 16 October 2006.
Antimicrobial Agents and Chemotherapy, December 2006, p. 4186-4188, Vol. 50, No. 12
0066-4804/06/$08.00+0 doi:10.1128/AAC.00494-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Tanaka, K., Mikamo, H., Nakao, K., Ichiishi, T., Goto, T., Yamagishi, Y., Watanabe, K.
(2009). In Vitro Activity of Tomopenem (CS-023/RO4908463) against Anaerobic Bacteria. Antimicrob. Agents Chemother.
53: 319-322
[Abstract]
[Full Text]
-
Morinaga, Y., Yanagihara, K., Nakamura, S., Yamamoto, K., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Yamada, Y., Kohno, S., Kamihira, S.
(2008). In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother
62: 1326-1331
[Abstract]
[Full Text]
-
Koga, T., Masuda, N., Kakuta, M., Namba, E., Sugihara, C., Fukuoka, T.
(2008). Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
52: 2849-2854
[Abstract]
[Full Text]
-
Mallalieu, N. L., Lennon, S., Liu, M., Kirkpatrick, C., Robson, R., Luedin, E., Davies, B. E.
(2008). Effect of Impaired Renal Function on the Pharmacokinetics of Tomopenem (RO4908463/CS-023), a Novel Carbapenem. Antimicrob. Agents Chemother.
52: 2360-2366
[Abstract]
[Full Text]
-
MacGowan, A. P., Bowker, K. E., Noel, A. R.
(2008). Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus Infection. Antimicrob. Agents Chemother.
52: 1401-1406
[Abstract]
[Full Text]